Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes.

J Immunol. 1996 Nov 15;157(10):4464-73. Unique Identifier : AIDSLINE MED/97064204
Malarkannan S; Gonzalez F; Nguyen V; Adair G; Shastri N; Department of Molecular and Cell Biology, University of; California, Berkeley 94720, USA.

Abstract: The identity and abundance of self-peptide/MHC class I complexes that serve as ligands for alloreactive T cells remain largely unknown. Using the Kb-restricted, alloreactive T cells as a probe, the Ag precursor gene, adenosine phosphoribosyl transferase (APRT), was isolated by expression cloning. Its naturally processed product was identified as the SLVELTSL (SEL8) octapeptide. The SEL8 peptide shared five residues with the previously identified SVVEFSSL (JAL8) peptide that stimulated the same T cell, but lacked the critical phenylalanine/tyrosine residue at the primary p5 anchor position. Despite the absence of this key conserved anchor residue, SEL8 was bound tightly by Kb MHC and yet was expressed at less than 10 copies/cell. Mutations in the donor APRT gene in the APC caused a concomitant loss in the ability of APCs to stimulate T cells. The results confirm that the display of peptide/MHC complexes in cells exceeds the predictions based upon consensus motifs, and that CD8+ alloreactive and conventional Ag-specific T cells are indistinguishable in their ability to recognize unique and rare peptide/MHC class I complexes.

Keywords: Animal Cell Line CD8-Positive T-Lymphocytes/*IMMUNOLOGY Epitopes/*IMMUNOLOGY Histocompatibility Antigens Class I/*IMMUNOLOGY Isoantigens/*IMMUNOLOGY Mice NAD+ ADP-Ribosyltransferase/ANALYSIS Peptides/*IMMUNOLOGY/METABOLISM Protein Binding/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
970228
M9721860

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .